![]() |
|
|
Departments of Pharmaceutics (B.L., D.D.S.), Medicinal Chemistry (W.H.), and Pharmacy (D.D.S.), University of Washington; and Clinical Research Division, Fred Hutchinson Cancer Research Center (B.L., B.P., L.L.R., D.D.S.), Seattle, Washington
Oxycodone undergoes N-demethylation to noroxycodone and O-demethylation to oxymorphone. The cytochrome P450 (P450) isoforms capable of mediating the oxidation of oxycodone to oxymorphone and noroxycodone were identified using a panel of recombinant human P450s. CYP3A4 and CYP3A5 displayed the highest activity for oxycodone N-demethylation; intrinsic clearance for CYP3A5 was slightly higher than that for CYP3A4. CYP2D6 had the highest activity for O-demethylation. Multienzyme, Michaelis-Menten kinetics were observed for both oxidative reactions in microsomes prepared from five human livers. Inhibition with ketoconazole showed that CYP3A is the high affinity enzyme for oxycodone N-demethylation; ketoconazole inhibited >90% of noroxycodone formation at low substrate concentrations. CYP3A-mediated noroxycodone formation exhibited a mean Km of 600 ± 119 µM and a Vmax that ranged from 716 to 14523 pmol/mg/min. Contribution from the low affinity enzyme(s) did not exceed 8% of total intrinsic clearance for N-demethylation. Quinidine inhibition showed that CYP2D6 is the high affinity enzyme for O-demethylation with a mean Km of 130 ± 33 µM and a Vmax that ranged from 89 to 356 pmol/mg/min. Activity of the low affinity enzyme(s) accounted for 10 to 26% of total intrinsic clearance for O-demethylation. On average, the total intrinsic clearance for noroxycodone formation was 8 times greater than that for oxymorphone formation across the five liver microsomal preparations (10.5 µl/min/mg versus 1.5 µl/min/mg). Experiments with human intestinal mucosal microsomes indicated lower N-demethylation activity (20-50%) compared with liver microsomes and negligible O-demethylation activity, which predict a minimal contribution of intestinal mucosa in the first-pass oxidative metabolism of oxycodone.
This article has been cited by other articles:
![]() |
K. K. Lemberg, A. O. Siiskonen, V. K. Kontinen, J. T. Yli-Kauhaluoma, and E. A. Kalso Pharmacological Characterization of Noroxymorphone as a New Opioid for Spinal Analgesia Anesth. Analg., February 1, 2008; 106(2): 463 - 470. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Sinatra Opioid Analgesics in Primary Care: Challenges and New Advances in the Management of Noncancer Pain J Am Board Fam Med, March 1, 2006; 19(2): 165 - 177. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Klees, P. Sheffels, O. Dale, and E. D. Kharasch METABOLISM OF ALFENTANIL BY CYTOCHROME P4503A (CYP3A) ENZYMES Drug Metab. Dispos., March 1, 2005; 33(3): 303 - 311. [Abstract] [Full Text] [PDF] |
||||